Bicycle Therapeutics (BCYC) Competitors

Immunic (NASDAQ:IMUX) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.

Do analysts prefer IMUX or BCYC?

Immunic currently has a consensus price target of $12.25, suggesting a potential upside of 1,055.66%. Bicycle Therapeutics has a consensus price target of $40.13, suggesting a potential upside of 84.14%. Given Immunic's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immunic is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33
Bicycle Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Is IMUX or BCYC more profitable?

Immunic has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
Bicycle Therapeutics	-450.64%	-27.35%	-20.81%

Which has higher earnings & valuation, IMUX or BCYC?

Immunic has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61M	-$1.23	-0.86
Bicycle Therapeutics	$26.98M	38.40	-$180.66M	-$3.29	-6.62

Which has more risk and volatility, IMUX or BCYC?

Immunic has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

Does the media prefer IMUX or BCYC?

In the previous week, Immunic had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 11 mentions for Immunic and 10 mentions for Bicycle Therapeutics. Immunic's average media sentiment score of 0.89 beat Bicycle Therapeutics' score of 0.44 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicycle Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals believe in IMUX or BCYC?

51.8% of Immunic shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 3.0% of Immunic shares are owned by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor IMUX or BCYC?

Bicycle Therapeutics received 35 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 70.16% of users gave Bicycle Therapeutics an outperform vote while only 64.71% of users gave Immunic an outperform vote.

Company	Underperform	Outperform
Immunic	Outperform Votes 99 64.71%	Underperform Votes 54 35.29%
Bicycle Therapeutics	Outperform Votes 134 70.16%	Underperform Votes 57 29.84%

Summary

Immunic beats Bicycle Therapeutics on 10 of the 18 factors compared between the two stocks.